To understand the cause of Parkinson's disease (PD), it is important to determine the functional interactions between factors linked to the disease. Parkin is associated with autosomal recessive early-onset PD, and controls the transcription of PGC-1a, a master regulator of mitochondrial biogenesis. These two factors functionally interact to regulate the turnover and quality of mitochondria, by increasing both mitophagic activity and mitochondria biogenesis. In cortical neurons, co-expressing PGC-1a and Parkin increases the number of mitochondria, enhances maximal respiration, and accelerates the recovery of the mitochondrial membrane potential following mitochondrial uncoupling. PGC-1a enhances Mfn2 transcription, but also leads to increased degradation of the Mfn2 protein, a key ubiquitylation target of Parkin on mitochondria. In vivo, Parkin has significant protective effects on the survival and function of nigral dopaminergic neurons in which the chronic expression of PGC1a is induced. Ultrastructural analysis shows that these two factors together control the density of mitochondria and their interaction with the endoplasmic reticulum. These results highlight the combined effects of Parkin and PGC-1a in the maintenance of mitochondrial homeostasis in dopaminergic neurons. These two factors synergistically control the quality and function of mitochondria, which is important for the survival of neurons in Parkinson's disease.
Introduction
Mitochondrial function is crucial for the survival of neurons, a cell type with high-energy demand and which is heavily dependent on oxidative phosphorylation (OXPHOS) for efficient ATP generation. Nigral dopaminergic neurons are constantly exposed to reactive oxygen species produced by dopamine metabolism (1) , and these neurons display a large and complex axonal arbor, which raises a major challenge for the trafficking of mitochondria and the supply of energy to their numerous synaptic connections (2) . Therefore, nigral dopaminergic neurons are highly dependent on effective mechanisms for the control of the quantity, quality and distribution of mitochondria. Hence, factors that disrupt the homeostasis of mitochondria, such as genetic mutations (3, 4) or toxins (4) , are often implicated in the progressive degeneration of nigral dopaminergic neurons that characterizes Parkinson's disease (PD).
In particular, mutations leading to the loss of Parkin function account for the most common familial forms of PD with autosomal recessive inheritance (5, 6) . In addition, sporadic PD is also associated with a decrease of Parkin activity (7) . The Parkin protein, which functions as an E3 ubiquitin ligase, plays a key role in the quality control of mitochondria via the regulation of mitophagy (8, 9) . The pathway regulating mitophagy is controlled by PINK1-mediated phosphorylation of Parkin and ubiquitin moieties, via a feed-forward mechanism leading to the ubiquitylation of mitochondrial proteins (10) (11) (12) . Among several targets, the poly-ubiquitination of PINK1-phosphorylated Mitofusin 2 (Mfn2) protein by Parkin contributes to the autophagic clearance of damaged mitochondria (13, 14) . However, Parkin-mediated mitophagy is most evident in immortalized cell lines exposed to uncoupling agents. Parkin translocation and mitophagy is observed only at a low rate in neuronal cells (15, 16) , which have a distinct metabolic profile from immortalized cell lines. Therefore, it is critical to explore the mechanisms that tightly control mitochondrial turnover in neurons.
In addition to the induction of mitophagy, Parkin has a multi-faceted role in controlling the function of mitochondria. Indeed, mitochondria exposed to stress can operate various mechanisms to preserve their homeostasis, such as organelle fusion/fission, and protein quality control systems including the generation of mitochondria-derived vesicles (MDV) and unfolded protein response (17, 18) . Parkin regulates key proteins involved in mitochondrial dynamics (19) , transport (20) and function (21) , either through non-degradative ubiquitination, or by promoting their proteasomal degradation (22) . In particular, Parkin has been shown to degrade the repressor PARIS, thereby promoting the transcription of PPARGC1A, a master regulator of mitochondrial biogenesis (23) . It has been proposed that the concerted action of Parkin and PGC-1a may have an important role by controlling the turnover of a functional pool of mitochondria (24, 25) , or more directly, by promoting mitochondrial repair (26) (27) (28) . Remarkably, a meta-analysis of gene expression in laser-captured dopamine neurons and substantia nigra (SN) has highlighted the down-regulation of PGC-1a activity in sporadic PD patients (29) , which prompts the clinical evaluation of disease-modifying treatments enhancing PGC-1a activity (30) .
Parkin and PGC-1a are two key proteins participating in the regulation of mitochondria homeostasis. Hence, understanding the interplay between these two factors is important to unveil the mechanisms that govern mitochondrial turnover in the context of PD. Here, we hypothesized that Parkin and PGC-1a may have combined effects on maintaining mitochondrial function. These effects were explored both in primary neuronal cell cultures, as well as in dopaminergic neurons in vivo. We observed that the cooperation of Parkin and PGC-1a increases mitochondrial density in cortical neurons. By maintaining a robust respiratory profile, these factors effectively rescue mitochondria from the loss of the membrane potential. In conditions where PGC-1a is continuously overexpressed in the rat SN, the activity of Parkin controls the survival of dopaminergic neurons and mitochondrial homeostasis, revealing the negative effects of the disease-associated Parkin mutants (25) .
Results

Overexpression of Parkin upregulates the transcription of PGC-1A
We first determined the effect of Parkin on the transcription of Ppargc1a in primary neurons derived from the mouse cortex. The amplicon used for quantification of Ppargc1a mRNA spans exons 10 and 11, a region which is present in most Ppargc1a splicing isoforms, including the previously described brainspecific isoforms (31) , but not in the N-terminal truncated isoforms (NT-PGC-1a). Ppargc1a mRNA level was significantly increased in primary neurons overexpressing human wild-type Parkin (Supplementary Material, Fig. S1A ). In neurons derived from Parkin-null mice, the basal expression of Ppargc1a was significantly reduced, which further confirmed a role of Parkin in regulating Ppargc1a expression. Parkin overexpression significantly rescued Ppargc1a mRNA level, whereas the K161N and R42P Parkin mutants associated with early-onset recessive PD had no significant effect (Supplementary Material, Fig. S1A ). Conversely, we examined whether PGC-1a overexpression induced any change in the transcription of PD-associated genes, and found no significant differences in the expression of Snca, Pink1, Park7 or Lrrk2 (Supplementary Material, Fig. S1B ). Park2 mRNA level was on average 38% reduced when PGC-1a was overexpressed, which was statistically not significant (P ¼ 0.09). Overall, these results confirmed that Parkin induces the expression of the transcriptional co-activator PGC-1a. Therefore, we next sought to explore the effects of these two factors on mitochondrial biogenesis.
Co-expression of Parkin and PGC-1a enhances both mitochondrial biogenesis and mitophagic activity
To assess the effects of Parkin and PGC-1a on the number of mitochondria, primary cortical neurons were transduced with AAV2/6 vectors encoding either Parkin or PGC-1a, or with a combination of these two vectors. Total vector doses were kept constant by adding the necessary amount of a non-coding control vector. Seven days post-infection, the relative numbers of mitochondrial DNA (mtDNA) copies per cell were determined by realtime PCR, measuring the abundance of a mitochondrial gene (MtCo2 or 16S) with respect to a nuclear gene (Ucp2 or Hk2) (Fig. 1A) . Relative mtDNA copy numbers were significantly increased in neurons overexpressing either PGC-1a or Parkin. And most remarkably, when these two proteins were co-overexpressed, the relative abundance of mtDNA was significantly further increased compared to all the other conditions. To obtain additional evidence for increased mitochondrial biogenesis, we infected neurons with a viral vector encoding the mitochondrial fluorescent reporter MitoDsRed. Transduced neurons were analysed by flow cytometry to determine the mean red fluorescence intensity as an indicator of total mitochondrial mass per cell (Fig. 1B) . Average MitoDsRed intensity was significantly increased in cortical neurons overexpressing either PGC-1a or Parkin. Again, the MitoDsRed intensity further increased when these two factors were co-expressed, confirming the combined effect of Parkin and PGC-1a on the density of mitochondria.
Next, we verified that mitochondrial biogenesis observed in neurons co-expressing PGC-1a and Parkin was not simply due to the increased transcriptional activity of PGC-1a in the presence of Parkin. To that end, mitochondrial biogenesis was evaluated in PGC-1a-null neurons. Neither the expression of Parkin, nor PGC-1a alone had an effect on mtDNA copies per cell (Fig. 1C) . Only when both factors were co-expressed, we observed an increase in mtDNA copy number. These findings demonstrate that Parkin has an effect on mitochondrial biogenesis only in the presence of PGC1a. In Parkin-null neurons however, Parkin and/or PGC-1a had clear effects on mtDNA abundance, which is similar to wild-type neurons (Fig. 1D) . Together, these results show that PGC-1a is the key factor driving mitochondrial biogenesis under these experimental conditions, and that Parkin and PGC-1a have synergistic effects on the abundance of mitochondria.
The number of mitochondria is controlled by both the biogenesis and mitophagic degradation of mitochondria. Using SH-SY5Y neuroblastoma cells, we determined the effect of coexpressing Parkin and PGC-1a on the rate of mitophagy. Cells were exposed to CCCP for 16 h to promote mitophagy, which was measured by co-expressing the mitochondria-targeted mKeima, a pH-sensitive fluorescent reporter resistant to lysosomal proteases (Fig. 1E) (32) . In contrast to PGC-1a, which alone To induce mitophagy, the cells are treated with 20 mM CCCP for 16 h. Scale bar: 10 mm. Red signal corresponds to the excitation of the ionized form of m-Keima in regions where mitophagy is on going. In cyan, non-ionized m-Keima signal is shown and represents mitochondria at pH 7. (F) The mitophagy index is measured by calculating the red/cyan ratio of the fluorescence intensity signal (number of replicates: 7-9 per condition, representing a total of 20-30 cells). A control condition with SH-SY5Y cells co-transfected with non-coding and m-Keima plasmids, and not exposed to CCCP, is shown for comparison. Statistical analysis for A, B and D: one-way ANOVA, followed by Newman-Keuls multiple comparison post-hoc test: *P < 0.05, **P < 0.01, ***P < 0.001. For C: one-way ANOVA with F(3,8)¼3.721, followed by unrestricted Fisher's LSD multiple comparison post-hoc test: *P < 0.05. For F: two-way ANOVA (all conditions except control without CCCP) with F(3,28)¼10.561 (PGC-1a x Parkin interaction), followed by Newman-Keuls multiple comparison post-hoc test: ns non-significant, *P < 0.05, ***P < 0.001. Data represent mean 6 SEM.
did not have any effect on mitophagic activity, overexpressing human Parkin increased mitophagy in SH-SY5Y cells exposed to CCCP (Fig. 1F) . Remarkably, the proportion of mitochondria present in the lysosomal compartment was higher in cells coexpressing Parkin and PGC-1a than in the Parkin alone condition (Fig. 1F ). This result indicates that Parkin and PGC-1a have combined effects both on the biogenesis and mitophagic degradation of mitochondria. In cortical neurons, Parkin and PGC-1a together maintain an abundant pool of mitochondria.
Parkin increases the maximal respiratory capacity of cortical neurons when PGC-1a is co-expressed
As the number of mitochondria increases following coexpression of PGC-1a and Parkin, it is important to determine the overall effect of these factors on mitochondrial metabolism. To this end, we measured the oxygen consumption rate (OCR), which is an important indicator of OXPHOS activity and mitochondrial function. The respiration of cortical neurons was measured under basal conditions as well as upon treatment with CCCP, a protonophore leading to mitochondrial uncoupling. Furthermore, to measure residual OCR in the absence of ATP production, separate wells were treated with oligomycin, an inhibitor of ATPase activity.
Similar to the previous experiment, cortical neurons were infected seven days before analysis with viral vectors that were either non-coding, encoding Parkin, or encoding PGC-1a. Expectedly, we observed that PGC-1a overexpression significantly increased basal OCR compared to control cells ( Fig. 2A and B). Neuronal respiration was further enhanced upon CCCP exposure. However, the maximal OCR of PGC-1a-expressing neurons in the presence of CCCP was only transiently increased, and the average respiration measured over 21 min of CCCP exposure was not significantly different compared to control ( Fig.  2A and D) . In cortical neurons co-expressing Parkin and PGC-1a, basal OCR was very similar to PGC-1a alone ( Fig. 2A and B) . However, upon CCCP treatment, we observed a robust and more sustained increase in OCR ( Fig. 2A) . The maximal OCR was significantly increased compared to neurons transduced either with the non-coding vector, or with AAV-PGC-1a (Fig. 2D) . The reserve respiratory capacity, which represents the percentage increase in OCR with respect to basal OCR, was dramatically enhanced only when PGC-1a and Parkin were co-expressed (Fig.  2C) . Measurement of OCR in the presence of oligomycin showed that there was no difference in the respiration dedicated to ATP production (% decrease in OCR), indicating that the coupling of mitochondrial respiration to the electron transport chain remained very similar across all three conditions (Fig. 2C ).
Next, we tested if the loss of Parkin activity caused by PD mutations suppresses the synergistic effect of Parkin and PGC1a on the mitochondrial respiratory capacity. Variants of human Parkin carrying the R42P mutation (defective in ubiquitin ligase activity) or the K161N mutation (defective in mitophagy) were co-expressed with PGC-1a. In contrast to wild-type Parkin, the two recessive PD-associated Parkin mutants failed to significantly increase the maximal respiratory capacity in primary cortical neurons (Fig. 2E) . The R42P mutant even further compromised mitochondrial activity. These results show that Parkin activity, combined with the expression of PGC-1a, enhances the mitochondrial respiratory capacity in neurons.
To determine if the effect of Parkin on CCCP-induced respiration is indeed potentiated by PGC-1a, we conducted a similar experiment to measure the effect of Parkin alone on mitochondrial respiration. Parkin overexpression did not induce any major change in basal OCR ( Fig. 2F and G) . Remarkably, we found that in the absence of PGC-1a overexpression, Parkin instead reduced the maximal OCR ( Fig. 2F and H) , consistent with a significant decrease in the respiratory reserve capacity (Fig.  2I) . Therefore, it appears that PGC-1a activity is critical for Parkin to increase the mitochondrial respiratory capacity and maintain a resilient pool of neuronal mitochondria, which exhibit robust metabolic activity under uncoupling stress.
Co-expression of PGC-1a and Parkin preserves the mitochondrial membrane potential Cellular respiration is critical to maintain the mitochondrial membrane potential (Dwm) via the electron transport chain (ETC) activity. To determine if PGC-1a and Parkin affect Dwm, we labelled primary cortical neurons with JC-1, a Dwm-sensitive dye that aggregates in polarized mitochondria and shifts its emission maximum from 525 nm (green) to 590 nm (red). Neurons were exposed to CCCP for 20 min, and then maintained in medium without CCCP. Although the ratio of green/red JC-1 fluorescence cannot be used to detect small variations in Dwm, red signal is an indicator of the presence of mitochondria which have recovered Dwm. We used JC-1 to assess Dwm recovery approximately 30 min after CCCP removal. As expected, the green/ red ratio was increased in control neurons following CCCP exposure (Fig. 3A) . Overexpression of either PGC-1a or Parkin alone only marginally enhanced Dwm recovery. In contrast, the coexpression of Parkin and PGC-1a had a robust effect on recovery of Dwm, and the ratio of green/red JC-1 fluorescence was similar to the level seen in neurons not exposed to CCCP (Fig. 3A) . When PGC-1a was co-expressed with either the R42P or the K161N Parkin mutant, Dwm did not significantly recover, highlighting the need for intact Parkin function. These results demonstrate that the increase in maximal respiration observed in neurons co-expressing Parkin and PGC-1a enhances their ability to regain Dwm following CCCP exposure.
Loss of Dwm is coupled with ROS production, which can impair the replication and integrity of mtDNA (33, 34) . Therefore, we sought to determine the effect of Parkin and/or PGC-1a expression in cortical neurons following longer exposure to CCCP. Neurons were exposed to 20 mM CCCP for 24 h, six days after transduction with AAV vectors. Real-time PCR was used to determine the amount of mtDNA (Mt-co2, 16S), relative to cellular gDNA (Ucp2, Hk2) (Fig. 3B ). Only the co-expression of Parkin and PGC-1a resulted in higher mtDNA copy numbers compared to neurons transduced with the non-coding vector. Neither the expression Parkin or PGC1a had a significant effect on mtDNA copy numbers.
PGC-1a and Parkin promote transcription of mitochondrial genes in cortical neurons
To explore how Parkin and PGC-1a co-regulate mitochondrial respiration and function, we next assessed by real-time PCR changes in the expression of several genes related to mitochondrial function, and that are transcriptionally controlled by PGC1a (23, 35, 36) . Transcriptional changes were measured in primary cortical neurons, seven days after transduction with AAV2/6 vectors encoding Parkin, PGC-1a, or a combination of these two vectors (Fig. 4) . Expectedly, several mitochondrial genes showed robust transcriptional changes in PGC-1a-overexpressing neurons. Genes showing significantly higher mRNA levels included Tfam, Atp5g1, Ndufs1, Cox4, Mfn1, Mfn2, Vdac1
and Clpp, whereas the expression of Rhot1 remained unchanged. The overexpression of Parkin alone also significantly increased the transcription of the same genes, which is consistent with the increase of PGC-1a activity observed in this condition (Supplementary Material, Fig. S1 ). For most of the upregulated genes, mRNA levels were very similar under conditions where either PGC-1a alone or PGC-1a together with Parkin was overexpressed. Nonetheless, compared to both the control and PGC-1a conditions, Parkin co-expression further increased the level of the mRNAs encoding Tfam and Ndufs1. Tfam is a mitochondrial transcription factor crucially implicated in the amplification of mtDNA and mitochondrial biogenesis. Ndufs1 is a key subunit of complex I, which transfers electrons from NADH to the respiratory chain and initiates OXPHOS. Therefore, the synergistic effect of Parkin and PGC-1a on the expression of Tfam and Ndufs1 is likely to contribute to the observed increase in the maximal respiration rate of cortical neurons co-expressing both factors.
However, Parkin does not appear to be a strong enhancer of the transcriptional activity of PGC-1a. Therefore, we sought to explore other possible mechanisms that may explain the robust synergistic effect between Parkin and PGC-1a on mitochondrial homeostasis (Figs 2 and 3). To this end, we measured if PGC-1a had any effect on the abundance of mitochondrial proteins, in particular those that are known substrates of Parkin-mediated ubiquitylation. . Two-tailed unpaired Student's t-test. All data represent mean 6 SEM. *P < 0.05, **P < 0.01.
PGC-1a controls the abundance of mitofusin 2, a substrate of Parkin
As Parkin primarily exerts E3 ubiquitin ligase activity, we next sought to determine if Parkin overexpression increases the ubiquitination of PGC-1a. SH-SY5Y neuroblastoma cells were transfected with plasmids encoding Parkin, EGFP-PGC-1a and ubiquitin, and the overexpressed EGFP-PGC-1a was immunoprecipitated to determine the ubiquitination level. Parkin overexpression did not increase levels of ubiquitinated PGC-1a, suggesting that PGC-1a is unlikely to be a substrate of Parkin (Supplementary Material, Fig. S2 ).
Next, we examined if PGC-1a controls the ubiquitination and degradation of Parkin substrates known to affect mitochondrial function. Parkin has been shown to control mitochondrial homeostasis via the ubiquitylation of proteins that are mainly present on the outer mitochondrial membrane (37) . Mitofusin 1 (Mfn1), Mfn2 and Voltage-Dependent Anion Channel 1 (VDAC1) are three substrates of Parkin that serve important roles in the function and turnover of mitochondria (14, 38, 39) . In order to assess the modification and degradation of these proteins independently of the effect of PGC-1a on the transcription of the corresponding endogenous genes, we used SH-SY5Y neuroblastoma cells transfected with a plasmid expressing either Mfn1, Mfn2 or VDAC1. Co-transfections were performed to determine the effect of Parkin and/or PGC-1a on the level and ubiquitination of the overexpressed tagged proteins. Parkin indeed induced the ubiquitination of Mfn1 in SH-SY5Y cells, but PGC-1a had no effect on the level of ubiquitinated Mfn1 (Fig. 5A ). VDAC1 also showed increased ubiquitination following Parkin expression. However, there was also no change in the overall level of VDAC1 in any of the conditions, and PGC-1a had no effect on the level of ubiquitinated VDAC1 (Fig. 5B) . Whereas PGC-1a did not influence the overall protein levels of Mfn1 and VDAC1, PGC-1a overexpression significantly reduced Mfn2 level in SH-SY5Y cells (Fig. 5C and D) . This effect was particularly evident in the absence of Parkin (Fig. 5C and D) . To determine which pathway was involved in Mfn2 degradation, we performed a similar experiment in the presence of either a protease inhibitor (MG-132) or an autophagy inhibitor (3-methyladenine, 3-MA). MG-132 prevented the reduction of Mfn2 levels seen in cells overexpressing PGC-1a ( Fig. 5C and D) . Therefore, Mfn2 degradation was likely mediated by the ubiquitin/proteasome system and/or calpain (40) , which are both blocked by MG-132. In SH-SY5Y cells treated with 3-MA, PGC-1a decreased Mfn2 levels to a similar extent as in untreated cells. In the presence of 3-MA, the effect of PGC-1a on Mfn2 was also significant in cells overexpressing Parkin. Together, these findings demonstrate that PGC-1a overexpression can induce the degradation of Mfn2 via mechanisms that are largely independent of Parkin and do not involve autophagy. As Mfn2 is the substrate of the mitochondrial E3 ubiquitin protein ligase 1 (MUL1), we analysed the expression of MUL1 in cells with increased PGC-1a activity. The protein levels of MUL1 were indeed increased in SH-SY5Y cells overexpressing PGC-1a (Supplementary Material, Fig. S4 ). Similarly, Mul1 mRNA levels were found to be higher in mouse cortical neurons overexpressing PGC-1a. PGC-1a may therefore modify the effects of Parkin on mitochondria by enhancing the turnover of the Parkin substrate Mfn2.
Parkin controls the survival of nigral dopaminergic neurons overexpressing PGC-1a and decreases amphetamine-induced rotational behaviour
Overexpression of PGC-1a modifies Parkin effects in cortical neurons by enhancing the biogenesis and the homeostasis of mitochondria. Next, we sought to explore the effect of Parkin and PGC-1a on dopaminergic neurons in the rat SN. Indeed, nigral dopaminergic neurons may critically depend on mitochondrial function to support their high metabolic demand (41, 42) . In addition, dopamine metabolism may cause oxidative stress and thereby compromise the mitochondrial function. Therefore, it is important to determine how Parkin and PGC-1a affect mitochondria quantity and quality in dopaminergic neurons in vivo. Despite the undisputed role of Parkin in familial PD, it has been notoriously difficult to assess its pathological effects in rodents. We explored the effects of Parkin in dopaminergic neurons overexpressing PGC-1a to induce mitochondrial biogenesis. Indeed, the chronic overexpression of PGC-1a leads to the selective loss of dopaminergic markers and neuronal degeneration in the rat SN and these effects may be in part caused by a failure of mitochondrial quality control (43) .
To determine if Parkin can rescue the PGC-1a-induced deficits observed in dopaminergic neurons in vivo, we co-expressed PGC-1a with either wild-type Parkin, or two of its mutated forms (R42P and K161N), using stereotaxic injections of AAV vectors. Co-injection of AAV-PGC-1a together with a non-coding vector was used for reference. The survival and function of nigral dopaminergic neurons was assessed at four months postinjection. Nissl staining was used to determine in the SN pars compacta the total number of neurons with a morphology similar to dopaminergic neurons ( Fig. 6B and Supplementary  Material, Fig. S4A ). In addition, VMAT2 was used as a marker to determine the number of nigral dopaminergic neurons (Fig. 6C  and Supplementary Material, Fig. S4B ). The overexpression of PGC-1a led to a progressive loss of nigral neurons in the injected SN (59 6 5% loss of Nissl þ neurons; 67 6 6% loss of VMAT2 þ cell bodies), compared to the contralateral hemisphere (Fig. 6A-C) .
In the striatum, the axonal immunoreactivity for tyrosine hydroxylase (TH) was decreased by 51 6 7% ( Fig. 6A and D) . Coexpression of wild-type human Parkin had a significant protective effect, decreasing the loss of Nissl þ neurons in the injected SN pars compacta to 43 6 5% ( Fig. 6A and B) . When measuring the number of VMAT2-positive neurons and striatal TH immunoreactivity, the Parkin group also showed a trend towards neuroprotection compared to the co-injection of a non-coding vector ( Fig. 6C and D) . The fact that it did not reach significance might indicate that Parkin had only a partial rescue effect on the dopaminergic markers.
In contrast to wild-type Parkin, the co-expression of the K161N or R42P Parkin mutants did not show any protective effect against the degeneration induced by overexpression of PGC-1a. In the SN pars compacta, the loss of VMAT2 þ and Nissl þ neurons in the groups expressing mutated Parkin reached values that were very similar to the co-injection of control non-coding vector, and significantly different from wildtype Parkin (Fig. 6A and C) . In the striatum, the decrease in TH immunoreactivity caused by the expression of PGC-1a was further exacerbated by the co-expression of either K161N (71 6 7%) or R42P Parkin (75 6 7%), as compared to the non-coding vector (51 6 7%). These results suggest a possible negative effect of mutant Parkin on the preservation of the dopaminergic innervation, which is significantly different from wild-type Parkin ( Fig.  6A and D) .
To evaluate the effects of Parkin on the dopaminergic function, we assessed amphetamine-induced rotations that reflect the motor asymmetry caused by dopamine release following amphetamine exposure. As previously shown (43), the chronic overexpression of PGC-1a led to motor asymmetry, with contraversive rotations reaching 3.54 6 1.02 turns/min at month 2, and 3.05 6 0.96 turns/min at month 4 after vector injection (Supplementary Material, Fig. S5A and B) . Two months after injection, wild-type Parkin significantly rescued motor asymmetry (1.36 6 0.41 turns/min). In contrast, the K161N and R42P mutants had no effect on the rotational behaviour caused by unilateral injection of the PGC-1a vector (Supplementary Material, Fig. S5B ). At 4 months post-injection, the difference between the group expressing PGC-1a, and the group expressing PGC-1a and Parkin was no longer significant, suggesting that Parkin-mediated effects on the motor function were transient in nature. This phenomenon might be due to a progressing neurodegeneration caused by PGC-1a overexpression.
Next, we assessed the effect of Parkin and mutants in the absence of PGC-1a. AAV vectors expressing wild-type Parkin, the K161N mutant and the R42P mutant were injected in the rat SN, using the same dose as in the previous experiment. Four months post-injection, we observed that Parkin mutants were expressed at lower levels compared to wild-type Parkin (Fig. 6E) , as previously reported for the R42P mutant (44) . Most importantly, both in the animals expressing Parkin and its mutated variants, there was neither a loss of neurons expressing TH in the SN pars compacta, nor a decrease of TH immunoreactivity in the striatum. Hence, only when nigral neurons in the adult SN overexpressed PGC-1a, did their survival depend on the induced expression of Parkin, revealing the lack of protective effect of the Parkin mutations under these conditions. Together, these findings support the hypothesis that Parkin activity can modify the survival of nigral neurons and the expression of dopaminergic markers in vivo, at least under conditions where PGC-1a is overexpressed.
Parkin and PGC-1a control the density and morphology of mitochondria in nigral dopaminergic neurons
To investigate how Parkin and PGC-1a activity determine the density and morphology of mitochondria in dopaminergic neurons, we performed a transmission electron microscopy (TEM) analysis on neuronal soma in the SN pars compacta, four months after vector injection. SN injected with either AAV-Parkin, AAV-PGC-1a, or the two vectors together, were compared to the control, non-injected hemisphere (Fig. 7A) .
We measured cytosolic mitochondrial density inside the soma of nigral neurons. Compared to control neuronal cell bodies, PGC-1a induced a significant increase in mitochondrial density (þ53%; Fig. 7B ). In contrast, overexpression of Parkin alone did not induce any significant change in the number of mitochondria. Nevertheless, compared to neurons overexpressing PGC-1a, co-expression of Parkin and PGC-1a normalized the density of mitochondria in the soma of nigral neurons.
Next, we analysed the effect of PGC-1a and Parkin on mitochondrial morphology. Two parameters were used: the circularity of mitochondrial sections, which has an inverse relationship with the elongation of this organelle (45) , and the surface of individual mitochondria sections. The overexpression of PGC-1a led to an increase of the average surface of mitochondrial sections, while Parkin did not appear to have any major effect on this parameter (Fig. 7A and D) . However, Parkin significantly reduced the circularity of neuronal mitochondria in the SN coinjected with the PGC-1a vector (Fig. 7C) . Collectively, the neurons co-expressing Parkin and PGC-1a displayed more elongated mitochondria, contrasting with the enlarged round mitochondria found following expression of PGC-1a alone ( Fig. 7A and D) . Furthermore, we noticed that the distribution of the sizes of individual mitochondria in neurons co-expressing Parkin and PGC-1a was more homogenous and remained closer to the control condition (Fig. 7D) . Overall, while PGC-1a overexpression increases the density and size of mitochondria in the soma of nigral dopaminergic neurons, the mitochondria are more sparse and elongated when Parkin is co-expressed.
Parkin and PGC-1a regulate the interaction of mitochondria with the endoplasmic reticulum
The interaction between mitochondria and the ER is critical for the dynamics of mitochondria (46) . In addition, the tethering of mitochondria to the ER depends on Mfn2 (47), which appears to be a key factor under the control of Parkin and PGC-1a. Next, we assessed in nigral neurons the abundance of contacts formed by the mitochondrial outer membrane with the ER (MAM) (Fig.  8A and B) . The mitochondria-ER association was analysed by measuring the proportion of mitochondrial sections making contacts with the ER membrane (Fig. 8B) . We found that PGC-1a had a strong effect on the presence of MAMs. In the SN injected with AAV-PGC-1a, the proportion of mitochondria associated with the ER was significantly increased to 57 6 3%, compared to the non-injected contralateral SN (39 6 2%). Remarkably, coexpression of Parkin counterbalanced the effects seen with PGC-1a alone. In the SN co-injected with the PGC-1a and Parkin vectors, MAM density was similar to when Parkin was overexpressed on its own. Overexpression of Parkin alone only slightly increased the percentage of mitochondria with MAM compared to control. These results suggest that Parkin activity may oppose the effects of PGC-1a on MAMs, possibly via the ubiquitylation of Mfn2. Next, we sought to explore in nigral dopaminergic neurons possible changes in lipofuscin deposition, an indicator of lysosomal activity, which has been linked to mitochondrial turnover. The number of lipofuscin granules was significantly decreased in nigral neurons overexpressing PGC1a, which may indicate PGC-1a-induced changes in the autophagic degradation of organelles including mitochondria (Fig. 8C) . In neurons overexpressing Parkin, PGC-1a did not lead to any significant difference in the number of lipofuscin granules.
Overall, Parkin appears to improve mitochondrial morphology in dopaminergic neurons overexpressing PGC-1a, mainly by normalizing mitochondrial density, promoting the elongation of mitochondria and reducing the number of contacts with the ER.
Discussion
We explored in neuronal cells the effects of co-expressing Parkin and the transcriptional co-regulator PGC-1a on the mitochondrial function. We found that co-expression of Parkin and PGC-1a induces mitochondrial turnover, exceeding the effects seen with PGC-1a alone. Furthermore, PGC-1a modifies the effects of Parkin on mitochondrial quality control and function. While Parkin alone decreases maximal respiratory rate in neuronal cells, Parkin in combination with PGC-1a enhances the neurons per condition). One-way ANOVA and Newman-Keuls multiple comparison post-hoc test for (B) and (C). *P < 0.05, **P < 0.01, ***P < 0.001, ns non-significant. mitochondrial maximal respiration rate and reserve respiratory capacity. Neurons co-expressing PGC-1a and Parkin showed a faster recovery of their mitochondrial membrane potential after CCCP exposure. Parkin and PGC-1a enhanced the transcription of mitochondrial genes including Tfam. Remarkably, PGC-1a also increased the degradation of Mfn2, a key ubiquitylation target of Parkin at the surface of mitochondria. In vivo, Parkin was found to mitigate the negative effects induced by the continuous overexpression of PGC-1a in the rat nigrostriatal system. Co-expression of Parkin significantly protects the nigral dopaminergic neurons. This effect is consistent with the presence of more elongated and more sparse mitochondria in the neuronal soma. Parkin also normalizes the mitochondria-ER interactions.
The Parkin/PGC1a axis and mitochondrial turnover
It has been shown that Parkin controls mitochondrial mass by inducing the proteasomal degradation of PARIS, a transcription repressor of PGC-1a (25) . Here, we show that co-expression of Parkin and PGC-1a leads to a dramatic increase in mitochondrial numbers in neuronal cells. As the effect of Parkin on mitochondrial density is abolished in PGC-1a null neurons (Fig. 1C) , PGC1a is likely to play a primary role in Parkin-induced mitochondria biogenesis. However, the additive effect of Parkin is not only explained by increased PGC-1a transcription via PARIS degradation. Indeed, Parkin can promote the expression of genes implicated in mitochondria biogenesis and OXPHOS. Parkin directly interacts with Tfam, a mitochondrial transcription factor that induces mtDNA replication and transcription of mitochondrial genes (48) . More recently, Parkin and PINK1 have also been shown to control the translation of components of the respiratory chain on the outer mitochondrial membrane (49) . Here, Parkin further enhances the transcription of Tfam and Ndufs1 in neurons expressing PGC-1a. Remarkably, PGC-1a overexpression also promotes the effect of Parkin on mitophagy in SH-SY5Y neuroblastoma cells. These factors that promote mitochondrial biogenesis and mitophagy appear to have coordinated functions in neurons. Parkin and PGC-1a are therefore critical factors, which control mitochondrial turnover and quality in conditions of mitochondrial stress.
Parkin and mitochondrial respiration
The role of Parkin in mitochondrial respiration has been previously shown in different models. Mice deficient for either Parkin or PINK1 display signs of mitochondrial dysfunction (50, 51) , and the maximal mitochondrial respiration is decreased in the striatum of Parkin null mice (51, 52) . More recently, defects in mitochondrial respiration have been reported in neurons following Parkin knockdown, or overexpression of the PGC-1a repressor PARIS, which is linked to Parkin deficiency (25) . In Drosophila, the loss of either Parkin or PINK1 reduces the turnover of many mitochondrial respiratory chain subunits (53) . Here, we find that the effect of Parkin on mitochondrial respiration depends on PGC-1a expression. Only when Parkin is co-expressed with PGC-1a do the neurons show a significant increase in the CCCPinduced maximal respiration. Therefore, Parkin likely cooperates with PGC-1a in controlling OXPHOS.
Parkin and mitochondrial repair
Repair mechanisms may be important to the homeostasis of mitochondria in neurons, particularly when these organelles are located distally to the cell body. In neurons co-expressing Parkin and PGC-1a, we observed a protection of Dwm in mitochondria transiently exposed to an uncoupling agent (Fig. 3A) . This effect is consistent with the observed increase in maximal respiration, which may facilitate the recovery of the membrane potential. PGC-1a could contribute to this effect by promoting the synthesis of proteins involved in OXPHOS, in conjunction with Parkin. Furthermore, Parkin may control the turnover of the respiratory complexes located in the inner mitochondrial membrane, although the mechanisms remain unclear. The ubiquitin-proteasome system controls the quality of mitochondrial components 1) by targeting proteins before or during their import into the organelle, or 2) via the retrotranslocation and degradation of mitochondrial proteins (54) . Parkin-dependent ubiquitination is found on proteins located inside the organelle following mitochondria depolarization (37) . Furthermore, Parkin induces the biogenesis of MDVs following oxidative stress within mitochondria (55) . MDVs contain damaged mitochondrial proteins, and may contribute to their lysosomal degradation, highlighting another role of Parkin in the control of mitochondrial quality. Parkin may also cooperate with PGC-1a in maintaining mitochondrial genome integrity (48, 56, 57) . We indeed measured higher mtDNA copy numbers in neurons overexpressing both PGC-1a and Parkin following 24 h of CCCP exposure (Fig. 3B) . Overall, the concerted action of Parkin and PGC-1a promotes the synthesis and quality control of mitochondrial proteins, mtDNA replication and repair, as well as the incorporation of lipids inside the mitochondria (58) , which collectively ensure the proper function of this organelle.
PGC-1a and Parkin regulate the level of Mfn2
Parkin targets preferentially targets proteins associated with the mitochondrial outer membrane, such as VDAC1 and mitofusins (37) . Upon mitochondrial depolarization, Parkin ubiquitylates mitofusins and promotes their degradation in a proteasome-and p97 (AAAþ ATPase)-dependent manner (59) . In SH-SY5Y neuroblastoma cells, PGC-1a induces Mfn2 degradation independently of Parkin, and in the absence of any mitochondrial stressor (Fig. 5 ). This effect is likely to be mediated by the induced expression of factors controlling the turnover of Mfn2. MUL1 can compensate for the loss of PINK1/Parkin function via the ubiquitin-dependent degradation of Mitofusin. Therefore, it might act in parallel to the PINK1/Parkin pathway on the mitochondrial quality control (60) . Although PGC-1a upregulates the expression of MUL1, it is needed to further explore the factors implicated in the induced degradation of Mfn2. As PGC-1a also up-regulates Mfn2 transcription (Fig. 4) , it may increase the overall turnover of this protein, which could have important effects on the dynamics of mitochondria (61), their interaction with the ER (62) and their transport along the axon (63) . Remarkably, a recent study has shown that the Mfn2 level is specifically increased at the MAM fraction isolated from the liver of Parkin null mice (64) .
The suppression of Mfn2 in the nigrostriatal dopaminergic system of floxed mice leads to a neurodegenerative phenotype characterized by severe loss of dopamine marker expression and decreased dopamine content in the striatum (65). This phenotype resembles what is observed in the nigrostriatal system of rats and mice continuously overexpressing PGC-1a (43, 66) . Moreover, dopaminergic neurons deficient for Mfn2 accumulate enlarged, spherical mitochondria (65), which are similar to the ones observed in rats overexpressing PGC-1a (Fig. 7) . Therefore, it is plausible that the increased degradation of Mfn2 induced by PGC-1a contributes to the defects observed in vivo.
In vivo effects of Parkin in nigral neurons expressing PGC-1a
Parkin and PINK1 null mice have failed to recapitulate the degeneration of dopaminergic neurons in the SN (67) (68) (69) . Furthermore, the loss of Parkin does not worsen the neurodegenerative phenotype of MitoPark mice (70) . Nevertheless, Parkin activity is critical to the survival of nigral dopaminergic neurons in Mutator mice, which have an accelerated mutation rate in mtDNA (71) . It is intriguing that Parkin enhances the survival and function of nigral dopaminergic neurons chronically overexpressing PGC-1a. Ultrastructural analysis has revealed a dramatic increase in mitochondria density in the soma of nigral dopaminergic neurons overexpressing PGC-1a (Fig. 7B) . This excess of mitochondria may create a situation where mitochondrial quality control is critically needed. Parkin reduces mitochondria density in nigral neurons expressing PGC-1a, in contrast to the increased number of mitochondria observed in mouse cortical neurons (Fig. 1) . Continuous PGC-1a expression in nigral dopaminergic neurons generates conditions that may challenge the quality control of mitochondria. In SH-SY5Y cells exposed to CCCP, the co-expression of Parkin and PGC-1a leads to robust mitophagic activity. Mitochondrial turnover could be similarly enhanced in nigral neurons co-expressing these two factors. In these neurons, mitochondria may indeed be exposed to chronic oxidative stress caused by dopamine metabolism, prompting the degradation of defective organelles. Furthermore, dopaminergic neurons have a unique morphology, with long axons and an extremely large number of synaptic connections (2) . Hence, the distribution of mitochondria inside the neurites is critically important. The density of mitochondria in the neuronal soma does not necessarily reflect the overall number of mitochondria present in nigral dopaminergic neurons.
Overall, we find that Parkin preserves mitochondrial homeostasis and enhances mitochondrial activity via its functional interaction with PGC-1a. Overall, the Parkin-PGC-1a axis has effects beyond the upregulation of PGC-1a transcription. In particular, the combined action of Parkin and PGC-1a appears as a potent regulator of mitochondrial biogenesis and quality control. This could have important implications in PD, as nigral dopaminergic neurons may critically depend on mitochondrial activity for their function and survival.
Materials and Methods
Primers, plasmids and antibodies
For the source of the antibodies and primer sequences, see the Supplemental Information (Supplementary Materials, Table S1 and S2). The plasmids are also described in the Supplemental Information.
Animals
For the source of animals, see the Supporting Information. All animals were housed in a 12 h light/dark cycle, with ad libitum access to food and water. All procedures were performed in accordance with Swiss legislation and the European Community Council directive (86/609/EEC) for the care and use of laboratory animals.
Production and titration of adeno-associated viral vectors
QuikChange Multi Site-Directed Mutagenesis Kit (Agilent Technologies) was used to generate the K161N and R42P Parkin mutants. The plasmid pRK5-HA-Parkin encoding HA-tagged human Parkin was used as a template. The Parkin cDNAs carrying the mutations were amplified by PCR and subcloned into the AAV-PGK-MCS plasmid using standard procedures. Methods for the production and the titration of AAV2/6 vectors have been previously described in details (72) . The infectivity titer of each vector was determined by real-time (rt) PCR (see Supplemental Information).
Western blot analysis
SH-SY5Y cells were lysed with NP-40 lysis buffer (1% NP-40, 150 mM NaCl, 50 mM Tris-Cl, pH 8.0) supplemented with cocktails of protease (Roche) and phosphatase inhibitors (Sigma). Protein samples were analysed by SDS-PAGE using standard procedures (see Supplemental Information).
Primary cortical neuron culture
Cortical neurons were dissected from E16 C57BL/6J mouse embryos (Janvier). Similar procedures were applied to obtain primary cortical neurons from genetically modified mice (see Supplemental Information).
Analysis of mRNA expression
Total mRNA was extracted using the Maxwell 
Mitochondria DNA quantification
Total DNA was extracted from neurons cultured in 24-well plates using the Maxwell V R 16 Viral Total Nucleic Acid Purification Kit (Promega), according to the manufacturer's instructions. For each sample, 10 ng of total DNA was applied as a template in the rt-PCR reaction. Primers used are summarized in Supplementary Material, Table S2 . The Rotor-Gene SYBR Green PCR kit (Qiagen) master mix was applied for rt-PCR DNA amplifications, which were analysed using an Applied Biosystems 7900HT Fast Real-Time PCR System. The ratio between mtDNA (Mt-co2, 16S) and genome DNA (Ucp2, Hk2) was calculated using the DDCT method.
Mitophagy index
The plasmid encoding the mitochondria-targeted m-Keima (pCHAC-mt-mKeima) was purchased from Addgene (#72342). To quantify mitophagy in individual cells, the m-Keima signal was imaged by live confocal microscopy. For imaging, cells were plated on glass coverslips and incubated in DMEM without phenol red, supplemented with 10% FBS and penicillin/streptomycin. Fluorescent samples were examined with a Zeiss LSM 710 confocal microscope (Carl Zeiss MicroImaging) equipped with a Plan-Apochromat 20Â/0.8 NA and 40Â/1.3 NA oil immersion objective lens. m-Keima fluorescence was imaged in two channels via two sequential excitations (458 nm, cyan; 561 nm, red) and using a 580-to 700-nm emission range. Laser power was set at the lowest intensity that would allow clear visualization of the m-Keima signal. Imaging settings were kept identical for all experimental conditions. Mitophagy quantification was performed as previously described (73) . Briefly, regions were defined manually for fluorescence and area measurements, on groups of whole cells. For each region measured, the mitophagy index was calculated as the ratio of the integrated density signals [561 nm/(561 nm þ 458 nm)], each value corrected for background using a control condition not transfected with the mKeima plasmid. The average of 7 to 9 independent regions, representing 20-30 cells in total, was measured for each condition. An arbitrary value of one was assigned to the average of the control condition þCCCP, and all samples were normalized to this value.
Flow cytometry analysis
Neurons infected with AAV2/6-MitoDsRed were resuspended in 100 mL Neurobasal medium without phenol red (Life Technologies). Neurons were dissociated with a gentle pipette trituration. The cells were analysed using an Accuri C6 flow cytometer (BD biosciences). Forward and side light scatters were used to gate the population of living cells. The fluorescent signal was acquired in FL2 channel, followed by analysis in software CFlow V R SAMPLER. FL2 gating was consistently applied across samples to exclude MitoDsRed-negative cells. Final data were represented as mean red fluorescence for single events in each sample.
Oxygen consumption measurement
Neurons were seeded in XF96 Polystyrene Cell Culture Microplates (Seahorse Bioscience) and infected with viral vectors. Two days before measurement, 75% of the culture medium was replaced by Neurobasal A medium (Gibco), supplemented with 2 mM glucose, 25 mM pyruvate, 100 U/mL Penicillin-Streptomycin, 2 mM Glutamax and B27. For the details of measurement, see Supplemental Information.
Mitochondria membrane potential measurement
The MitoProbe TM JC-1 Assay Kit (Life Technologies) was used to assess the mitochondrial membrane potential (Dwm). All procedures followed the manufacturer's instructions. See Supplemental Information for details.
Stereotaxic injection
Stereotaxic injections of the AAV2/6 vectors in the rat SN were performed as previously described (43) . See Supplemental Information for details.
Behavioural test
Ipsiversive rotations induced by intraperitoneal injection of amphetamine (D-amphetamine sulfate, 2.5 mg/kg; Sigma) were measured in individual rats to assess asymmetry in the dopamine signalling in the basal ganglia. The procedure was carried out as described previously (43) . Rotametry was performed before vector injection (pre-test), and was repeated at 2 and 4 months post-injection.
Histology and quantification
Animals were sacrificed four months post-vector injection and brain tissue was processed as described previously (72) . See Supplemental Information for details.
Transmission electron microscopy
Four months post-injection, animals were deeply anaesthetized, perfused, and subjected to electron microscopy analysis. See Supplemental Information for details. Three animals were used for each condition. For relative quantification of changes in organelle morphology, 50 nm-thick sections from the SN pars compacta were systematically imaged in a transmission electron microscope (FEI Company) operated at 80 kV. For each SN, we analysed eight randomly chosen largesize neuronal soma, identified by the presence of the cell nucleus. Dopaminergic neurons were recognized based on their morphology. Cellular and nuclear membranes, as well as mitochondria were outlined manually using the ImageJ software. Mitochondria number, size and circularity were measured using the Particle Analyzer tool. Mitochondria density is represented as the number of mitochondria normalized to the measured surface of the cytosol. The size and circularity of mitochondria were measured for each individual organelle, which was considered as a replicate for statistical analysis. Lipofuscin granules and MAMs were labelled and quantified using Cell Counter tool. MAM was defined as a close contact between mitochondria and ER (< 20 nm).
Statistics
Data are presented as average 6 standard error of the mean (SEM). Statistical analysis was performed using the prism 6 software (version 6.0c). Two-tailed unpaired homoscedastic Student's t-test, one-and two-way ANOVA followed by Fischer's LSD or Newman-Keuls multiple comparison post-hoc test were applied for analysing data with normal distribution. Kruskal-Wallis test followed by Dunn's multiple comparison post-hoc test was applied for mitochondria size. The alpha level of significance was set at 0. 
Supplementary Material
Supplementary Material is available at HMG online. 
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